August 31, 2021
AstraZeneca has submitted an application in Japan seeking an additional indication of its EGFR inhibitor Tagrisso (osimertinib) as an adjuvant therapy for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), the company’s local arm said on August 30. The...read more